[Research progress on prostate-specific membrane antigen ligand positron emission tomography imaging of prostate cancer].

Prostate cancer is the most common malignant tumor in male urinary system, and the morbidity and mortality rate are increasing year by year. Traditional imaging examinations have some limitations in the diagnosis of prostate cancer, and the advent of molecular imaging probes and imaging technology have provided new ideas for the integration of diagnosis and treatment of prostate cancer. In recent years, prostate-specific membrane antigen (PSMA) has attracted much attention as a target for imaging and treatment of prostate cancer. PSMA ligand positron emission tomography (PET) has important reference value in the diagnosis, initial staging, detection of biochemical recurrence and metastasis, clinical decision-making guidance and efficacy evaluation of prostate cancer. This article briefly reviews the clinical research and application progress on PSMA ligand PET imaging in prostate cancer in recent years, so as to raise the efficiency of clinical applications.前列腺癌是男性泌尿系统最常见的恶性肿瘤，其发病率及死亡率均逐年上升。传统影像学检查在诊断前列腺癌方面具有一定的局限性，而分子影像探针与成像技术的问世，为前列腺癌的诊疗一体化提供了新的思路。近年来，前列腺特异性膜抗原（PSMA）作为前列腺癌成像和治疗靶点备受关注，PSMA配体正电子发射计算机断层显像（PET）在前列腺癌原发灶的诊断、初始分期、生化复发与转移的检测、临床决策指导及疗效评估方面均具有重要参考价值。本文就近年来PSMA配体PET显像在前列腺癌的临床研究与应用进展作简要综述，以期提高其临床应用效益。.